Skip to content
Open access · OA via Europe PMC

Mitochondrial Dysfunction and Bioenergetics in Chronic Obstructive Pulmonary Disease: Mechanisms, Biomarkers, and Therapeutic Opportunities.

Bhat R, Dunne LB, Miles S, Kazi A, Siddiqui D, Warriach MN, Ofoegbu CT, Vellani Z.

The Yale journal of biology and medicine · 2026

Abstract

Chronic obstructive pulmonary disease (COPD) is a heterogeneous lung condition characterized by chronic respiratory symptoms and persistent obstruction of airflow arising from abnormalities of the airways and/or alveoli. Its pathogenesis includes multiple interacting exposures and susceptibilities, including cigarette smoking, biomass and occupational exposures, air pollution, and genetic factors. Per this paradigm, researchers have historically focused on developing broad anti-inflammatory therapeutics that manage acute symptoms but fail to arrest progressive decline. Within this heterogeneous disease framework, mitochondrial dysfunction(definition) may contribute to chronic obstructive pulmonary disease pathobiology through interactions with oxidative stress, inflammation, impaired quality control, and altered cellular bioenergetics. We evaluate mitochondrial-associated biomarkers for disease severity, progression, and patient stratification, while considering their limited specificity and susceptibility to confounding by aging and comorbidities. We also assess the limitations of broad-spectrum antioxidant strategies and examine mitochondrial-targeted antioxidants and metabolic modulators, such as SS-31, MitoQ, and metformin. In addition, the review examines emerging mitochondrial stress pathways, including OMA1-DELE1-HRI signaling, while emphasizing that their direct involvement in chronic obstructive pulmonary disease remains unestablished. Altogether, the evidence available supports mitochondrial biology as a complementary area of investigation within the broader inflammatory, structural, and metabolic heterogeneity of chronic obstructive pulmonary disease, while our review reveals that substantial mechanistic and clinical validation remains necessary.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
Europe PMC
DOI
10.59249/uvmv3274
Canonical
link ↗
Fetched
2026-11-13 MST

Cite this

APA
R, B., LB, D., S, M., A, K., D, S., MN, W., CT, O., &amp; Z., V. (2026). Mitochondrial Dysfunction and Bioenergetics in Chronic Obstructive Pulmonary Disease: Mechanisms, Biomarkers, and Therapeutic Opportunities. <em>The Yale journal of biology and medicine</em>. https://doi.org/10.59249/uvmv3274
Vancouver
R B, LB D, S M, A K, D S, MN W, et al. Mitochondrial Dysfunction and Bioenergetics in Chronic Obstructive Pulmonary Disease: Mechanisms, Biomarkers, and Therapeutic Opportunities. The Yale journal of biology and medicine. 2026. doi:10.59249/uvmv3274.
BibTeX
@article{bhat2026Mitoch, title = {Mitochondrial Dysfunction and Bioenergetics in Chronic Obstructive Pulmonary Disease: Mechanisms, Biomarkers, and Therapeutic Opportunities.}, author = {Bhat R and Dunne LB and Miles S and Kazi A and Siddiqui D and Warriach MN and Ofoegbu CT and Vellani Z.}, journal = {The Yale journal of biology and medicine}, year = {2026}, doi = {10.59249/uvmv3274}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings